Article
Pregnancy outcomes following maternal or paternal exposure to teriflunomide in the Danish MS population
22 Jan 2022
Abstract excerpt
Background Teriflunomide (TFL) is an oral drug used for treatment of multiple sclerosis (MS). Due to possible teratogenicity it is contraindicated in women of childbearing potential. Additionally, a low risk of male-mediated embryo-fetal toxicity has been described as the drug can be transmitted via semen. This study investigated the association of adverse perinatal outcomes in newborns with either maternal or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
